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Pyruvate Dehydrogenase Kinase 4 
Promotes Vascular Calcification via 
SMAD1/5/8 Phosphorylation
Sun Joo Lee1,*, Ji Yun Jeong2,12,*, Chang Joo Oh2,*, Sungmi Park3, Joon-Young Kim2,13,  
Han-Jong Kim2,14, Nam Doo Kim4, Young-Keun Choi2, Ji-Yeon Do3, Younghoon Go2,  
Chae-Myeong Ha2, Je-Yong Choi5,15, Seung Huh6, Nam Ho Jeoung7, Ki-Up Lee8,  
Hueng-Sik Choi9, Yu Wang10, Keun-Gyu Park2,3, Robert A. Harris11 & In-Kyu Lee2,3,15
Vascular calcification, a pathologic response to defective calcium and phosphate homeostasis, is 
strongly associated with cardiovascular mortality and morbidity. In this study, we have observed 
that pyruvate dehydrogenase kinase 4 (PDK4) is upregulated and pyruvate dehydrogenase complex 
phosphorylation is increased in calcifying vascular smooth muscle cells (VSMCs) and in calcified 
vessels of patients with atherosclerosis, suggesting that PDK4 plays an important role in vascular 
calcification. Both genetic and pharmacological inhibition of PDK4 ameliorated the calcification in 
phosphate-treated VSMCs and aortic rings and in vitamin D3-treated mice. PDK4 augmented the 
osteogenic differentiation of VSMCs by phosphorylating SMAD1/5/8 via direct interaction, which 
enhances BMP2 signaling. Furthermore, increased expression of PDK4 in phosphate-treated VSMCs 
induced mitochondrial dysfunction followed by apoptosis. Taken together, our results show that 
upregulation of PDK4 promotes vascular calcification by increasing osteogenic markers with no 
adverse effect on bone formation, demonstrating that PDK4 is a therapeutic target for vascular 
calcification.
Vascular medial calcification is prevalent in patients with diabetes, chronic renal failure (CRF), and in 
aging. It contributes to the high cardiovascular risk associated with hypertension, left ventricular hyper-
trophy, and compromised coronary perfusion1–3. It results from transdifferentiation of vascular smooth 
1Department of Biomedical Science, Graduate School of Medicine, Kyungpook National University. 2Department 
of Internal Medicine, Kyungpook National University. 3Leading-edge Research Center for Drug Discovery and 
Development for Diabetes and Metabolic Disease, Kyungpook National University. 4New Drug Development 
Center, Daegu-Gyeongbuk Medical Innovation Foundation. 5Department of Biochemistry and Cell Biology, 
Kyungpook National University. 6Department of Surgery, Kyungpook National University, Daegu, Republic 
of Korea. 7Department of Fundamental Medical and Pharmaceutical Sciences, Catholic University of Daegu, 
Gyeongsan, Republic of Korea. 8Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
of Medicine, Seoul, Republic of Korea. 9National Creative Research Initiatives Center for Nuclear Receptor Signals 
and Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, 
Gwangju, Republic of Korea. 10State Key Laboratory of Pharmaceutical Biotechnology and Department of 
Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China. 11Roudebush VA Medical Center 
and the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, 
IN, USA. 12Department of Internal Medicine, Soonchunhyang University Gumi Hospital, Gumi, Republic of Korea. 
13GIST College, Gwangju Institute of Science and Technology. 14Research Institute of Clinical Medicine, Chonnam 
National University Hwasun Hospital, Gwangju, Republic of Korea. 15BK21 plus KNU Biomedical Convergence 
Programs at Kyungpook National University, Daegu, Republic of Korea. *These authors contributed equally to 
this work. Correspondence and requests for materials should be addressed to R.A.H. (email: raharris@iu.edu) or 
I.-K.L.(email: leei@knu.ac.kr)
Received: 29 June 2015
Accepted: 12 October 2015
Published: 12 November 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:16577 | DOI: 10.1038/srep16577
muscle cells (VSMCs) into osteogenic cells in response to bone morphogenetic protein 2 (BMP2) signa-
ling4,5. Under pro-calcific stimuli such as high inorganic phosphate (Pi) in serum from CRF patients6 or 
in the presence of toxic levels of vitamin D7,8, BMP2 binds its receptor, BMP2-activated type 2 receptor 
(BMPR-2), to initiate a signaling cascade9. Activation of BMPR-2 triggers formation of a receptor com-
plex that activates the protein kinase BMP2-activated type 1 receptor (BMPR-l)10. Activated BMPR-1 
phosphorylates small mothers against decapentaplegic (SMAD) 1/5/8, which move into the nucleus 
where they assemble into a transcriptional machinery that regulates expression of genes that mediate the 
osteogenic switch5,10. These genes include Runt-related transcription factor 2 (RUNX2), alkaline phos-
phatase (ALP), and matrix protein osteocalcin (BGLAP)11–14.
Pyruvate dehydrogenase kinase (PDK) 4 is a key enzyme for regulation of glucose oxidation via inhi-
bition of the pyruvate dehydrogenase complex (PDC)15 by phosphorylation of PDHE1α (a subunit of 
PDC) in mitochondria. High levels of PDK4 are associated with dysregulation of glucose metabolism in 
diabetes16,17. In this study, we examined whether upregulation of PDK4 is required for vascular calcifica-
tion. Several factors that induce vascular calcification also increase PDK4 expression; these include glu-
cocorticoids18,19, cAMP via protein kinase A20,21, angiotensin II22,23, and LXR agonists24,25. Furthermore, 
vascular calcification and PDK4 expression are strongly attenuated by insulin19,26. Since PDK4 regulates 
PDC in the mitochondrial matrix space27 and SMAD1/5/8 are located in the cytosol and nucleus10, 
direct regulation of SMAD1/5/8 by PDK4 has not been considered physically possible. However, under 
conditions that promote calcification such as high Pi, or toxic levels of vitamin D, extra PDK4 activity 
might play a role in regulating osteogenic gene expression, in which it promotes vascular calcification 
by directly phosphorylating SMAD1/5/8, in addition to inducing mitochondrial dysfunction followed by 
apoptosis. These findings delineate a novel role for PDK4 in vascular calcification and suggest that this 
enzyme is a promising drug target for the treatment of patients with vascular calcification.
Results
PDK4 expression is correlated with osteogenic differentiation in human calcified vessels. The 
expression profile of PDK isoenzymes in vascular calcification was evaluated in human VSMCs treated 
with high concentrations of Pi to induce calcification. The mRNA and protein levels of PDK4 were 
markedly increased in a time-dependent manner as well as dose-dependent manner, whereas expression 
of other PDK isoenzymes (Pdk 1, 2, and 3) was not significantly altered (Fig. 1a). The amount of phos-
phorylated PDHE1α (p-PDHE1α ), a subunit of pyruvate dehydrogenase complex (PDC) and surrogate 
marker of PDK activity, was also increased in Pi-treated human VSMCs (Fig. 1b and Supplementary Fig. 
S1). Incubation of VSMCs with Pi also induced expression of mineralization-regulating genes such as 
BMP2, RUNX2 (known as Cbfa1), VDR, SP7 (known as Osterix), matrix protein such as BGLAP (known 
as osteocalcin) and IBSP (known as bone sialoprotein), and counter-regulatory genes such as SMAD6 and 
SPP (known as osteopontin),9 as well as upregulation of PDK4 (Fig. 1c).
We next tried to determine whether PDK activity is increased in calcified vessels of patients with 
atherosclerosis. Because antibodies suitable for immunohistochemistry are not available for the meas-
urement of the PDKs by this technique, we determined the phosphorylation status of PDHE1α as an 
indirect measure PDK activity. Since the PDKs phosphorylates serines 293 and 300 of PDHE1α 28, phos-
phorylation site-specific antibodies were used to examine the level of p-PDHE1α in calcified vessels from 
8 patients with atherosclerosis (medical information for these patients is provided in Supplementary 
Table S1) relative to non-calcified vessels from a healthy donor after brain death. Expression of both 
p-PDHE1α Ser293 and Ser300 were significantly increased in the calcified lesions, as defined by calcium 
deposition in calcified vessels from those patients relative to non-calcified regions of the same vessels 
(Fig. 1d and Supplementary Fig. S2). Since we find that PDK4 is the only PDK that increases under con-
ditions that promote calcification, these findings suggest PDK4 is upregulated by conditions that promote 
upregulation of osteogenic gene markers and calcification in human vessels and VSMCs.
Genetic and pharmacological inhibition of PDK4 prevent vascular calcification. To further 
pursue the possibility that PDK4 plays an important role in vascular calcification, aortic VSMCs from 
PDK4−/− mice were cultured in media that promote calcification. Calcium deposition was significantly 
reduced in calcified VSMCs from PDK4−/− mice (Fig.  2a). Similar results were obtained with ex vivo 
aortic rings prepared from WT and PDK4−/− mice based on von Kossa staining after Pi-induced calci-
fication (Fig. 2b). To evaluate the effect of PDK4 deletion in an in vivo model, mice were treated with 
high doses of vitamin D3, which has been shown to induce medial calcification in different animal 
models7,29,30. WT mice exhibited remarkable calcification in the aortas after vitamin D3 treatment, which 
was significantly reduced in PDK4−/− mice (Fig.  2c). (Additional physiological parameters for vitamin 
D3-induced calcification mouse models are shown in Supplementary Figure S3a–c.) We confirmed that 
Pi-induced calcification in VSMCs was significantly attenuated by siRNA-mediated PDK4 mRNA knock-
down (80 ± 3% of control with 100 nM siRNA) (Fig. 2d).
Concomitantly, DCA31, a general pharmacological inhibitor of the PDK isoforms, attenuated the cal-
cification of VSMCs in a dose-dependent manner as assessed by von Kossa staining and calcium lev-
els (Fig.  3a) and decreased Pi-induced p-PDHE1α Ser 293/300 levels (Fig.  3b and Supplementary Fig. 
S3d). DCA attenuated the calcification of rat aortic rings ex vivo (Fig. 3c and Supplementary Fig. S3e) 
and vascular calcification in vitamin D3-treated mice in vivo (Fig.  3d). The experimental schedule of 
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DCA treatment in vitamin D3-treated mice is shown in supplementary Figure S3f,g. Overexpression of 
PDK4 by adenoviral delivery-Pdk4 (Ad-Pdk4) in human VSMCs significantly increased calcification in 
a dose-dependent manner that was effectively attenuated by DCA (Fig. 3e). Taken together, the findings 
with DCA suggest that PDK4 is a promising target for the treatment of vascular calcification.
Figure 1. PDK4 is upregulated in the development of vascular calcification. (a) mRNA (left) and 
protein (right) expression of PDK isoenzymes during Pi-induced calcification in human VSMCs in a time-
dependent and dose dependent manner (n = 4). *P < 0.05 compared with day 0. †P < 0.05 compared with 
untreated control. (b) Immunofluorescence staining and quantification of total PDHE1α and p-PDHE1α 
during Pi-induced calcification in human VSMCs (n = 4). Scale bar = 20μ m. (c) Expression of osteogenic 
genes and PDK4 in Pi-induced human VSMCs on day 3 (n = 3). *P < 0.05 compared with untreated control. 
(d) Representative immunohistochemical results for p-PDHE1α S293/S300 in calcified vessels of patients 
with vascular calcification, compared to a non-calcified control. Scale bar = 200 μ m. Data presented in 
graphs represent means ± S.E.M.
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PDK4 augments the osteogenic switch in VSMCs. Upregulation of osteogenic gene expression 
is a key cellular process in vascular calcification5. PDK4 overexpression by Ad-Pdk4 in human VSMCs 
increased both mRNA expression of osteogenic genes and increased promoter activity of Runx2 and Alpl 
in a dose-dependent manner, with no change of Bmp2 mRNA expression (Fig. 4a,b and Supplementary 
Fig. S4a). The increased expression of Alpl mRNA by Pdk4 overexpression was reversed by DCA treat-
ment (Supplementary Fig. S4b). Likewise, master osteogenic regulators were significantly reduced in 
Pi-treated VSMCs obtained from PDK4−/− mice compared to WT mice (Fig. 4c). Interestingly, overex-
pression of PDK4 did not alter BMP2 expression, in contrast to the increase in BMP2 expression caused 
by incubating human VSMCs in Pi-containing media (Fig. 4a,b and Fig. 1d). Because Bmp2 promoter 
activity did not increase with PDK4 overexpression (Fig. 4b), we tested whether Bmp2 expression was 
altered in VSMCs from PDK4-/- mice under physiological condition. The expression of Bmp2 did not 
change in these cells in the absence of Pi (Supplementary Fig. S4c). Under Pi-treated condition, we 
Figure 2. Vascular calcification is attenuated by PDK4 knockdown. (a) Calcium deposition in Pi-induced 
primary VSMCs from WT and PDK4−/− mice (n = 5 per groups). *P < 0.05 compared with untreated 
control. †P < 0.05 compared with WT treated with Pi. (b) H&E staining and von Kossa staining of cross-
sections of descending aorta rings ex vivo cultured with Pi from WT and PDK4−/− mice (representative 
samples with n = 3 per groups). Scale bar = 100 μ m (c) Vitamin D3-induced calcium deposition (left) and 
score (right) in aortas from WT and PDK4−/− mice (representative samples with n = 5 per experimental 
group, n = 3 per control group). *P < 0.05 compared with untreated control. †P < 0.05 compared with WT 
treated with Pi. (d) Calcium deposition and quantification by acute PDK4 siRNA knockdown in human 
VSMCs (n = 3). *P < 0.05, **P < 0.01 compared with the corresponding control. Data presented in graphs 
represent means ± S.E.M.
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Figure 3. Vascular calcification is suppressed by dichloroacetate (DCA), a pharmacological inhibitor 
of PDK. (a) Calcium deposition (left) and score (right) in Pi-induced human VSMCs in the presence of 
the indicated concentrations of DCA (n = 3). *P < 0.05 compared with Pi-untreated control. †P < 0.05 
compared with Pi-treated control. (b) Western blot analysis (left) and immunofluorescence analysis (right, 
green) for p-PDHE1α S293/S300 in human VSMCs on day 3 after Pi treatment with or without DCA. 
Nuclei were stained with DAPI (blue) (n = 4). Scale bar = 50 μ m. (c) H&E staining, calcium deposition, and 
corresponding p-PDHE1α S293 of cross-sections of Pi-treated rat common carotid arteries ex vivo with or 
without DCA (n = 5). Scale bar = 100 μ m. (d) Vitamin D3-induced calcium deposition in aortas of DCA-
treated and –untreated WT mice (n = 5 mice per group). *P < 0.05 compared with Vitamin D3-untreated 
control. †P < 0.05 compared with Vitamin D3-treated control. (e) Calcium score measured in human 
VSMCs infected with Ad-Pdk4 compared to control (left) and calcium deposition by PDK4 overexpression 
(Ad-Pdk4) with different concentrations of DCA co-treatment (right) (n = 3). *P < 0.05 compared with Pi-
untreated control. †P < 0.05 compared with Ad-CMV. Data presented in graphs represent means ± S.E.M.
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observed that Bmp2 expression was only increased by PDK4 overexpression at late time points (4days) 
(Fig. 4d), suggesting that PDK4 may indirectly affect BMP2 expression only after Pi-treatment.
Since PDK4 upregulated expression of several osteogenic genes which are induced by BMP2, we 
postulated that PDK4 may be involved in BMP2 downstream signaling without affecting the expres-
sion and promoter activity of BMP2 itself. We tested whether PDK4 alters the phosphorylation state 
of SMAD1/5/8, downstream components of the BMP2 signaling pathway that, when phosphorylated, 
Figure 4. The levels of PDK4 are positively correlated with osteogenic markers. (a) mRNA levels of 
osteogenic genes measured in human VSMCs after infection with Ad-Pdk4 (n = 3). *P < 0.005 compared 
with Ad-CMV. (b) Luciferase activity measured in HEK293 cells after transfection with a Pdk4 vector and 
luciferase reporter constructs for fragments of Runx2 (− 4615/+ 60), Alpl (1.9 kb), and Bmp2 (− 2712/+ 165) 
(n = 3). *P < 0.05 compared with Con (pc DNA) vector. n.s, non-significance. (c) RT-PCR analysis of 
osteogenic genes in VSMCs from WT and PDK4−/− mice cultured with Pi (n = 3). *P < 0.05, **P < 0.01 
compared with WT. (d) RT-PCR analysis of Bmp2 gene expression in human VSMCs infected with Ad-CMV 
or Ad-Pdk4 (n = 3). **P < 0.01 compared with Ad-CMV. (e) Immunostaining for p-SMAD1/5/8 in human 
VSMCs after Ad-CMV or Ad-Pdk4 infection. p-SMAD1/5/8 (red), DAPI for nuclei (blue). Scale bar = 50 μ m. 
(f,g) Western blots of p-SMAD 1/5/8 and total SMAD 1/5/8 in human VSMCs infected with Ad-CMV 
or Ad-Pdk4 (f) and Effect of DCA on p-SMAD1/5/8 during calcification (g). Data presented in graphs 
represent means ± S.E.M.
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translocate into the nucleus to activate expression of osteogenic genes32. The immunofluorescence 
analysis data showed that PDK4 overexpression increased nuclear translocation of p-SMAD in human 
VSMCs, consistent with increased p-SMAD protein expression (Fig. 4e,f). The enhanced p-SMAD 1/5/8 
expression in calcifying media was suppressed by DCA treatment (Fig. 4g).
Next, we investigated the underlying mechanism by which PDK4 upregulated osteogenic genes 
induced by BMP2. We confirmed that the phosphorylation level of SMAD1/5/8 was consistently upreg-
ulated by PDK4 after BMP2 induction, which was diminished by DCA treatment (Fig. 5a,b). Likewise, 
PDK4 overexpression augmented the levels of p-SMAD 1/5/8 after BMP2 induction in C2C12 cells and 
human VSMCs (Fig.  5c and Supplementary Fig. S4d). To monitor the effect of PDK4 overexpression 
on SMAD1/5/8 transcriptional activity, C2C12 cells were transfected with a vector carrying a luciferase 
reporter under the control of a BMP response element, the sequence that SMAD1/5/8 bind to pro-
mote transcription by BMP2 (Fig. 5d). As expected, overexpression of PDK4 in C2C12 cells resulted in 
increases in p-SMAD1/5/8 levels after BMP2 induction and potentiated the transcriptional activity of 
BMP2 (Fig. 5c,d). This data demonstrates that an increase in p-SMAD1/5/8 mediated by PDK4 plays an 
important role in regulating osteogenic gene expression under calcifying conditions.
PDK4 directly binds to and phosphorylates SMAD1/5/8. Because PDK4 and SMAD1/5/8 are 
located in different subcellular compartments, a direct interaction between PDK4 and SMAD seems 
unlikely. Conversely, it has been reported that SMAD5 is present in the mitochondria of a human chon-
drogenic cell line33, and the mammalian PDK4 orthologue in Caenorhabditis elegans is dual-localized 
in the cytosol and mitochondria34. Therefore, these reports raised the possibility of a direct interaction 
between PDK4 and SMADs. Furthermore, the MitoProt ІІ algorithm program predicts with high proba-
bilities (86.5% to 91.7%) that mouse and human SMAD1/5/8 have mitochondrial targeting sequences of 
24 to 30 amino acids. Because transfection efficiency is poor with human primary VSMCs, co-localization 
studies in these cells are not feasible. Therefore, confocal imagining analysis of the subcellular localiza-
tion of PDK4 and SMAD proteins was conducted with C2C12 cells, which like VSMCs increase PDK4 
expression and undergo calcification in a high Pi media (Supplementary Fig. S5a,b). As expected, overex-
pressed PDK4 was predominantly localized in mitochondria and partially in the cytosol whereas SMAD 
1 and 5 were mainly localized in the cytosol and partially in the mitochondria (Supplementary Fig. 
S6a). Furthermore, immunostaining using confocal microscopy revealed colocalization of PDK4 and 
SMAD1/5 in the cytosol of PDK4-overexpressing C2C12 cells (Fig. 6a). When we performed immunob-
lots of PDK4 and SMAD5 with cytosolic and mitochondrial fractions of C2C12 cells expressing Pdk4, 
SMAD5 and PDK4 were detected in both the mitochondrial and the cytosolic fraction (Fig. 6b). These 
Figure 5. The level of p-SMAD is augmented by PDK4 activity in BMP induction. (a,b) Immunoblot 
analysis of p-SMAD1/5/8 and SMAD1/5/8 in human VSMCs infected with Ad-CMV or Ad-Pdk4 under 
BMP2 (20 ng/ml) stimulation for indicated number of hours (a) with indicated concentrations of DCA (b) 
(n = 3). (c) Immunostaining for p-SMAD1/5/8 (left) and SMAD1/5/8 (right) in C2C12 cells infected with 
control retrovirus (Vxy) or retrovirus expressing Pdk4 after stimulation with BMP2 (50 ng/ml) (n = 3). Scale 
bar = 50 μ m. (d) C2C12 cells infected with control retrovirus or Pdk4 expressing retrovirus were transfected 
with a BMP/luciferase reporter (BRE-Luc) containing Bmp2 response element (12XGCGC). Cells were 
stimulated for 48 h with BMP2 (n = 3). *P < 0.05, **P < 0.01 compared with control (Vxy). Data presented in 
graphs represent means ± S.E.M.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:16577 | DOI: 10.1038/srep16577
Figure 6. PDK4 directly interacts with SMAD1/5/8. (a) Immuno-fluorescence images of C2C12 cells 
infected with control retrovirus or Pdk4-expressing retrovirus. The sections were co-stained with antibodies 
for PDK4 (green), SMAD1, SMAD5, SMAD1/5 (red), and DAPI (blue). Colocalization was confirmed by a 
LSM5 ZEISS exciter (white). Scale bar = 10 μ m. (b) Western blot for SMAD5 and PDK4 in mitochondrial 
and cytosolic extracts from C2C12 cells infected with control retrovirus or Pdk4 expressing retrovirus 
(n = 3). (c) Co-immunoprecipitation analysis of C2C12 infected with control (Vxy) or C-terminal Flag 
epitope-tagged Pdk4-expressing retrovirus. (d) GST pull-down assays with GST-PDK4 and 35S-labelled 
SMADs. (e) In vitro kinase assay with [γ -32P]-ATP showing phosphorylation of SMAD1, SMAD5, and 
SMAD8 by PDK4 (black arrow), auto-phosphorylation of PDK4 (positive control, gray arrow). (f) Structure 
osf the complex showing the S463 and S465 phosphorylation sites of the SMAD5 and PDK4 complex. (g) In 
vitro kinase assay showing the phosphorylation of SMAD5 by indicated doses of PDK4 proteins. (h) In vitro 
kinase assay showing that DCA inhibits the phosphorylation of SMAD5 and auto-phosphorylation induced 
by PDK4. (i) The elimination of SMAD5 phosphorylation by mutation of S463 and S465 of SMAD5 to Ala 
(SMAD5 AVA). Data presented in graphs represent means ± S.E.M.
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data showed the possibility of direct interaction between PDK4 and SMAD1/5/8 in the cytoplasm as 
well as mitochondria.
We further investigated this potential interaction by co-immunoprecipitation from PDK4-expressing 
C2C12 cells. PDK4 bound tightly to SMAD1 and SMAD5 but not SMAD4 (Fig.  6c). To confirm the 
physical interaction, SMAD proteins were prepared by in vitro transcription/translation and incubated 
with a GST-PDK4 fusion protein. SMAD1, SMAD5, and SMAD8, but not SMAD4, were pulled down 
by GST-PDK4 (Fig.  6d). The experiment using PDK4 prepared by in vitro transcription/translation 
and immobilized GST-SMADs further confirmed that PDK4 directly interacts with SMAD1, SMAD5, 
and SMAD8, but not with SMAD4 (Supplementary Fig. S6b). Based on an in vitro kinase assay, PDK4 
directly phosphorylated SMAD1/5/8 (Fig.  6e). To validate the interaction between PDK4 and SMAD, 
a protein-protein interaction model was developed based on the structure of ADP-bound PDK4. This 
model predicted that residues Asn397, Phe400, and Met454 located within the ATP-lid of PDK4 inter-
act with residues Arg323, Pro315, and Val318 that surround the Ser463 and Ser465 in SMAD5 that are 
phosphorylated by BMP receptor 1 (Fig.  6f). Considerable amino acid sequence identity (31% of 45 
residues) and similarity (additional 29%) exists in the ATP-binding domains of PDK4 and BMP receptor 
135. Phosphorylation of SMAD5 was markedly increased by PDK4 in a dose-dependent manner (Fig. 6g), 
and DCA decreased this activity of PDK4 (Fig. 6h). DCA also inhibited auto-phosphorylation of PDK4 
(Fig.  6h) by a direct inhibitory effect upon PDK436. SMAD5 also inhibited auto-phosphorylation of 
PDK4 (Fig.  6h), consistent with SMAD5 being a better substrate than PDK4 itself. Phosphorylation 
of SMAD5 by PDK4 was completely blocked by replacing Ser463 and Ser465 of SMAD5 with alanine 
residues (sites that are phosphorylated by BMPR-1) (Fig. 6i). Taken together, these findings indicate that 
PDK4 binds SMAD1/5/8 and phosphorylates SMAD5 (and most likely SMAD1/8) on the same residues 
that are phosphorylated by BMPR-1.
PDK4 exacerbates apoptosis and mitochondrial dysfunction in calcified VSMCs. The oxi-
dative stress and consequent apoptosis in VSMCs play a critical role in the pathogenesis of vascular 
calcification37. In addition, the primary role of PDK4 is as an important regulator in mitochondria 
for transforming pyruvate into acetyl-CoA by PDC. Previously, we reported that α -lipoic acid, which 
also inhibits PDK438, attenuates vascular calcification and Pi-induced apoptosis of VSMCs by improv-
ing mitochondrial function and the intracellular redox status39. Therefore, we evaluated the effects of 
PDK4 on mitochondrial function and reactive oxygen species (ROS) generation in VSMCs. As shown in 
Fig. 7a, caspase-3 activity increased in human VSMCs after Pi treatment and DCA reversed the increase. 
Likewise, PDK4 significantly increased caspase-3 activity under high-Pi media (Fig.  7b). According to 
the TUNEL assay, Pi-stimulated apoptosis was blunted by the PDK pharmacological inhibitor DCA 
(Fig. 7c).
To determine the effects of PDK4 on mitochondrial respiratory function, we measured ATP contents 
and oxygen consumption rate (OCR). Ad-Pdk4 infected human VSMCs induced mitochondrial dysfunc-
tion, demonstrated by decreased ATP content, whereas this was ameliorated by DCA treatment (Fig. 7d). 
Basal oxygen consumption rate (OCR) and maximal respiration capacity were also reduced in C2C12 
cells that were infected with retrovirus expressing Pdk4 (Fig. 7e). DCA reversed the negative effects of 
PDK4 overexpression (Fig. 7e). These results indicate that PDK4 reduces mitochondria function which 
may contribute to the pathogenesis in vascular calcification.
In addition, DCA treatment blocked Pi-induced mitochondrial ROS generation (Fig. 7f), a well-known 
pro-apoptotic factor that promotes calcification of VSMCs. Moreover, Ad-Pdk4 infected human VSMCs 
increased mitochondria ROS generation (Fig. 7g) and DCA treatment blocked PDK4 induced mitochon-
drial ROS generation (Fig. 7g). These findings suggest that PDK4 exacerbates vascular calcification not 
only by promoting BMP-SMAD signaling but also by inducing mitochondrial-dependent apoptosis and 
mitochondrial dysfunction.
PDK4 deficiency does not adversely affect bone remodeling. The processes involved in vascular 
calcification and osteoblast differentiation for bone formation are similar29,40,39. Therefore, we examined 
whether PDK4 affects bone remodeling by two types of pre-osteoblasts, MC3T3E1 and bone marrow stro-
mal cells (BMSCs) derived from PDK4−/− and WT mice. Osteoblast differentiation and the expression of 
osteoblast marker genes such as Alpl, Runx2, and Tnfrsf11b (also known as Opg) decreased in MC3T3E1 
cells infected with Ad-Pdk4, consistent with von Kossa staining and ALP activity (Supplementary Fig. 
S7a–c). Likewise, mineralization detected by von Kossa staining, ALP activity, and expression of oste-
ogenic gene markers were increased in bone marrow stem cells (BMSCs) from PDK4−/− mice com-
pared to WT (Supplemental Fig. S7d–f), indicating that PDK4 induced opposite effects in VSMCs and 
pre-osteoblasts. Although PDK4 deletion produced positive effects on osteoblastogenesis, consistent with 
a previous report41, the micro-computed tomography (micro-CT) of the femurs from PDK4−/− and WT 
mice at 17 weeks of age showed no differences in parameters including bone mineral density, bone 
surface/bone volume, bone volume/tissue volume ratios, trabecular separation, trabecular thickness, tra-
becular number, and cortical BMD (Fig.  8). Thus, deletion of PDK4 effectively ameliorated vascular 
calcification without adverse effects on bone remodeling.
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Figure 7. PDK4 exacerbates apoptosis and mitochondrial dysfunction in calcified VSMCs. (a) Caspase 
3 activity in Pi-treated human VSMCs with or without DCA (n = 4). *P < 0.05 compared with untreated 
control. †P < 0.01 compared with Pi-treated control. (b) Caspase 3 activity in human VSMCs infected with 
Ad-CMV or Ad-Pdk4 with or without Pi treatment (n = 5). *P < 0.05 compared with Ad-CMV (c) TUNEL 
staining in human VSMCs during calcification with or without DCA. Scale bar = 100 μ m. (d) ATP contents 
in human VSMCs infected with Ad-CMV and Ad-Pdk4 with different DCA concentrations (n = 3). *P < 0.05 
compared with Ad-CMV. †P < 0.05 compared with Ad-Pdk4 50 MOI. (e) Oxygen consumption ratio in C2C12 
cells infected PDK4 expressing retrovirus and Vxy and DCA effect. After basal OCR determination, cells were 
treated with oligomycin, CCCP, and rotenone in these cells. DCA (1 mM) was treated in these cells (n = 5). 
(f) Mitochondrial ROS (MitoTracker Red) in human VSMCs during calcification induced by Pi and DCA 
treatment. (g) Mitochondrial ROS (MitoTracker Red) in human VSMCs infected Pdk4 expressing retrovirus 
and Vxy after DCA treatment. (n = 3). Scale bar = 50 μ m. Data presented in graphs represent means ± S.E.M.
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Discussion
This study provides the first evidence that PDK4 plays an important role in osteogenic switching in 
VSMCs by direct phosphorylation of SMAD1/5/8 under calcifying conditions. Concomitantly, we found 
that p-PDHE1α Ser293 and Ser300 are increased in calcified regions of the vessels from patients with 
vascular diseases, suggesting that enhanced PDK activity presumably due to increased PDK4 expression 
occurs during vascular calcification. On a molecular basis, we propose that PDK4 activates SMAD1/5/8 
by phosphorylation, which leads to translocation of p-SMAD into the nucleus for transcriptionally reg-
ulating osteogenic markers in a similar manner to the BMP2 signaling pathway. Accordingly, significant 
similarity exists in the primary amino acid sequences of the ATP-binding and kinase domains of PDK4 
and BMPR-1, and the serine phosphorylated by PDK4 at site 1 in PDHE1α is in the same sequence con-
text (SXS) as the motif phosphorylated in SMAD1/5/8 by BMPR-1. A unique kinetic property of PDK4 
favors its ability to phosphorylate SMAD1/5/8. In the free form the basal activities of the other PDK 
isoforms is low and only becomes significant upon binding to the core of the PDC. In contrast, the free 
form of PDK4 exhibits robust enzyme activity towards suitable substrates in the absence of the PDC36.
Interestingly, PDK4 overexpression by itself does not induce vascular calcification mediated by the 
phosphorylation of SMAD, demonstrating that additional modification of PDK4 by canonical BMP sig-
naling might be necessary for kinetic activity of SMAD under calcification conditions. Since PDK4 is 
located in the mitochondrial matrix, phosphorylation of SMAD1/5/8 by PDK4 is unexpected. Although 
this dilemma was not fully resolved in this study, findings to support our data have been reported. 
Chen et al. provided evidence that pyruvate dehydrogenase phosphatase (PDP) 1, the counterpart of 
PDK4 for regulation of PDC activity, dephosphorylates SMAD1 directly in vertebrates and the analo-
gous protein MAD (mothers against decapentaplegic in Drosophila), even though PDP1 was believed to 
be located exclusively in mitochondria42. Consistently, the phosphorylation state of DAF8 in C. elegans, 
the orthologue of vertebrate SMAD 1/5/8, is also regulated by PDP143. These observations suggest PDP 
is a dual-localized cytosolic/mitochondrial enzyme. Our immunohistochemical data and western blot 
analysis indicate that both PDK4 and SMAD can localize in both the cytosol and the mitochondria 
during calcification. This phenomenon is supported by recent results showing that PDHK2, the ortho-
logue of PDK4, activates SKN-1, the orthologue of Nrf2, by phosphorylation in the cytosol of C. elegans, 
suggesting that PDK is also dual-localized in the cytosol and mitochondria34,44. Consistent with our 
data, PDHK2 is found in the mitochondria dominantly at very low levels in well-nourished states, and 
is partially distributed to the cytosol by starvation of C. elegans34. Furthermore, it has been reported 
that PDK4 directly binds and regulates the cAMP-response element-binding protein (CREB), which is 
known to be located in the cytosol45. Taken together, these results suggest that that PDP1 and PDK4 are 
Figure 8. PDK4 knockdown does not adversely affect normal bone remodeling. (a) Representative 
Micro-CT image of distal femurs from WT and PDK4−/− mice. (b–h) Bone morphometric parameters of 
the femurs from WT and PDK4−/− mice. (b) Trabecular bone mineral density (BMD), (c) Bone surface/
bone volume (BS/BV; spatial distribution of trabeculae), (d) Bone volume/tissue volume (BV/TV: amount 
of trabecular bone within the cancellous space), (e) Trabecular separation (Tb. Sp), (f) Trabecular thickness 
(Tb. Th), (g) Trabecular number, (h) Cortical BMD from WT and PDK4−/− mice (n = 5 per group). Data 
presented in graphs represent means ± S.E.M.
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dual-localized cytosolic/mitochondrial enzymes that participate in the regulation of the phosphorylation 
state of SMAD1/5/8 in humans under pathological conditions.
Since PDK4 plays a prohibitory role in glucose oxidation associated with mitochondrial dysfunction, 
increased caspase activity and decreased ATP generation followed by apoptosis during calcification were 
ameliorated by DCA treatment. The recent observation that a shift toward glycolytic breakdown of glu-
cose occurs during vascular calcification46 is consistent with high expression of PDK4 and decreased 
PDC activity found in the present study. We have also observed that glucose consumption and lactate 
production are increased in Pi-induced VSMC calcification (data not shown). Further studies will be 
required to ascertain the changes in metabolism in VSMCs during vascular calcification and its relation-
ship with PDK4.
Intensive efforts have been made to identify therapeutic targets for the prevention of vascular calcifi-
cation because similar processes and key factors are involved in osteogenesis in both vascular calcifica-
tion and physiologic bone formation. The inhibitory effect of vascular calcification might adversely affect 
bone remodeling14,47,48. In this study, VSMCs under calcifying media and ex vivo ring calcification as well 
as vitamin D3-induced aortic calcification in vivo were significantly attenuated in PDK4-deficient mice. 
Even though PDK4 promotes osteogenic switching in VSMCs under calcifying stimuli, bone remodeling 
and osteoblastic differentiation in pre-osteoblasts was not adversely affected by PDK4 deficiency. Instead, 
consistent with our data, PDK4−/− mice are protected from bone loss induced by unloading41. Last, a 
number of clinical and experimental studies have shown an increase in the incidence of vascular calci-
fication and osteoporosis49,50, further highlighting the potential of PDK4 as a therapeutic target for the 
treatment of vascular calcification without adverse effects on bone formation.
Methods
Human Tissues. The study protocol was approved by the institutional review board and the Regional 
Board of the Ethics Committee of the Kyungpook National University Hospital (IRB 2012-10-022) and 
informed consents were obtained from the subjects. All experiments were performed in accordance with 
approved guidelines of Kyungpook National University. Blood vessels were obtained from 8 patients 
who underwent vasculoplasty due to atherosclerosis at Kyungpook National University Hospital, Daegu, 
South Korea. Detailed medical information for the patients is provided in Online Table І. Human VSMCs 
and healthy vessels for immunohistochemistry were prepared from thoracic aortas of kidney transplanta-
tion donors, obtained using a modified explants method as described in the Data Supplement, and were 
used for experiments at passages 5–7.
Mouse model of vitamin D3-induced aortic calcification. All experiments were approved by the 
Institutional Animal Care and Use Committee of Kyungpook National University (KNU 2012-83). All 
experiments were performed in accordance with approved guidelines of Kyungpook National University. 
A vitamin D3-induced aortic calcification mouse model is well established in this laboratory51. 
Six-week-old C57BL/6N male mice were subjected to gavage daily with sterile water as control or with 
dichloracetate (DCA; Sigma-Aldrich, St. Louis, MO, USA, Cat # D54702) (50 mg kg−1) for 13 days. At 
day 3 after the initial treatment with DCA, the mice were subcutaneously administered vitamin D3 
(cholecalciferol; Sigma-Aldrich, Cat # C9756, 5.5 × 105 IU kg−1 day−1) daily for 3 days. Seven days after 
the final exposure to vitamin D3, mice were anesthetized with pentobarbital (50 mg kg−1) and whole 
aortas were collected by surgical dissection to determine calcium content. The colony of PDK4-deficient 
(PDK4−/−) mice52 was established in an in-house animal facility. Six-week-old C57BL/6J WT and 
PDK4−/− male mice were subcutaneously administered vitamin D3 (C57BL/6J; 4.5 × 105 IU kg−1 day−1) 
daily for 3 days. Thirteen days after the final exposure to vitamin D3, mice were anesthetized as described 
before. Animals were maintained on a 12-h light/12-h dark cycle. All animals used in the experiments 
were age- and sex-matched and littermates.
Immunohistochemistry. The vessels were routinely processed for paraffin embedding at a thickness 
of 10 μ m after 4% paraformaldehyde fixation for the analysis. For details of immunohistochemistry, refer 
to the supplementary material method.
Induction of in vitro VSMC calcification. VSMCs were seeded at a density of 1.3 × 104 cells per 
cm2 and maintained for 2 days until sub-confluent. Calcification was induced by DMEM (high glucose) 
supplemented with 10% FBS and an additional 2.6 mM Pi (a mixture of Na2HPO4 and NaH2PO4, pH 
7.4) that borough the final Pi concentration to 3.5 mM). The calcification medium was changed every 2 
days for 8 days.
Antibodies. Anti-p-PDHE1α (S293, S300) (Calbiochem, San Diego, CA, USA, AP1062-1064, 
respectively) were used for immunohistochemistry. Anti-p-PDHE1α (S293, S300) (Abfrontier), 
anti-SMAD1/5/8 (Santa Cruz Biotechnology, Dallas, TX, USA, sc-6031-R), anti-p-SMAD 1/5/8 (Cell 
Signaling Technology, Danvers, MA, USA, #9511), COXIV (Abcam, Cambridge, UK, ab16056) and 
anti-Flag (Sigma-Aldrich, F1804) antibodies were used for both immunofluorescence and western blot-
ting. Anti-SMAD1 (Invitrogen, Carlsbad, CA, USA, #38-5400), anti-SMAD5 (Abgent, San Diego, CA, 
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USA, AJ1726a), and anti-SMAD1/5 (Santa Cruz Biotechnology, sc-6201) were used for immunofluores-
cence. Anti-α -tubulin (Applied Biological Materials, G098), anti-lamin B (Santa Cruz Biotechnology, 
sc-6216), anti-SMAD4 (Cell Signaling Technology, #9515) and anti-PDK4 serum (Abfrontier) were used 
for western blotting.
GST tagged protein and in vitro kinase assay. Full-length human SMAD1, mouse Smad5, and 
rat Smad8 were inserted into the EcoR1 and Xho1 sites of the pGEX4T-1 vector for expression as a 
glutathione-S-transferase (GST) fusion protein and amplified in Escherichia coli BL21. The GST-tagged 
human SMAD1, mouse SMAD5, rat SMAD8, human SMAD4, and mouse PDK4 proteins were puri-
fied for an in vitro kinase assay by incubation with glutathione-Sepharose TM4B (GE Healthcare, 
Sweden) at room temperature for 20 min, followed by extensive washing of the beads with PBS. 
[35S]-Methionine-labeled mouse PDK, human SMAD1, mouse SMAD5, and rat SMAD8 proteins were 
synthesized in vitro using a TnT Quick Coupled Transcription/Translation System (Promega, Madison, 
WI, USA). The washed glutathione-Sepharose beads were incubated with [35S]-methionine-labeled 
mouse PDK4, human SMAD1, mouse SMAD5, or rat SMAD8 in binding buffer (25 mM HEPES, pH 
7.6, 1 mM DTT, 100 mM NaCl, 0.2 mM EDTA, 1.5% BSA, 20% glycerol) at 4 °C for 12 h. Sepharose beads 
were washed twice with PBS and boiled with SDS-PAGE sample buffer, and the supernatant proteins 
were resolved in SDS-PAGE gels.
Binding model prediction of PDK4 and SMAD5. The structure of PDK4 in complex with ADP 
was obtained from the Protein Data Bank (http://www.pdb.org, pdb code: 2E0A). Discovery Studio3.5 
(http://www.accelrys.com) with MODELLER was used for the homology model building of SMAD5. For 
details of binding model prediction of PDK4 and SMAD5, refer to the supplementary material method.
Cell culture and transient transfection. Mouse VSMCs were isolated from the thoracic aortas of 
5 week old male C57BL/6J mice. Cells were used for experiments after 4 to 5 passages. Human VSMCs 
were isolated from the thoracic aortas of kidney transplantation donors. For details of cell culture, refer 
to the supplementary material method.
Immunohistochemistry. Ethics approval was obtained from the Institutional Review Board of the 
Kyungpook National University Hospital for all studies with human tissues and the collection of med-
ical data. Informed consent was obtained for all studies with human tissues. The section after fixation 
by PFA and embedding by paraffin were used for immunohistochemistry analysis. Tissue sections were 
deparaffinized followed by the retrievation of antigens using steamer (IHCWORLD, IW-1102) at 95 °C 
for 40 min in 0.01 M citrate buffer, pH 6.0. For the visualization of p-PDHE1α S293 and S300 in arter-
ies, the sections were incubated with antibodies against p-PDHE1α S293 and S300 overnight at 4 oC 
before detection with rabbit IgG and mouse IgG antibody by UltraVision LP Detection System (Thermo 
Scientific). Nuclei were counterstained with Mayer’s Hematoxylin (Lillie’s Modification).
Quantification of Calcium Deposition. For measuring calcium deposited in the extracellu-
lar matrix of the cells calcium contents in the supernatant were determined colorimetrically by the 
o-cresolphthaleincomplexone method (Bioassay System, Cat.DICA500). For details of quantification of 
calcium deposition, refer to the supplementary material method.
Immunofluorescence analysis. Human VSMC attached on glass in a 6-well plate at a density of 
2 × 105 per well, grew to confluence, and were further incubated in the absence or presence of extra 
Pi for the indicated times. The cells were fixed with 4% PFA for 15 min and permeabilized with 0.1% 
Triton X-100 for 15 min at room temperature. The permeabilized cells were incubated with antibody for 
PDHE1α , SMAD1, SMAD5, SMAD1/5 and p-SMAD1/5/8 in zymogen Ab diluents solution overnight at 
4°C followed by the incubation with Alexa Fluor-488-conjucated anti-rabbit secondary antibody, Fluor-
568-conjugated anti-mouse secondary antibody (Molecular Probes) for 3 h at room temperature. The 
nuclei were counterstained in blue with 4’, 6-diamidino-2-phenylindole (DAPI; 5 μ g ml−1, Molecular 
Probes) and mounted in Vectashield (VECTOR LABORATORIES). The images were visualized with an 
inverted MRc5 Carl Zeiss fluorescence microscope (Thornwood, NY) and OLYMPUS CLASM FV-100.
Adenovirus-mediated overexpression of PDK4 in VSMCs. Recombinant adenovirus express-
ing PDK4 was provided by Dr. Young-Bum Kim (Harvard Medical School, MA). For details of 
Adenovirus-mediated overexpression of PDK4 in VSMCs, refer to the supplementary material method.
GST pull-down assay. Full-length human SMAD1, mouse Smad5 and rat Smad8 were inserted into 
the EcoR1 and Xho1 sites of the pGEX4T-1 vector and amplified in E. coli BL21. Proteins were quantified 
using Coomassie Blue staining. [35S]-Methionine labeled-mouse PDK4, human SMAD1, mouse SMAD5, 
rat SMAD8 proteins were synthesized in vitro using TnT Quick Coupled Transcription/Translation 
System (Promega). GST and GST fused proteins were incubated with Glutathione-Sepharose TM4B (GE 
Healthcare) at room temperature for 20 min. Sepharose beads were washed with PBS and incubated 
with [35S]-methionine-labeled proteins in binding buffer (25 mM HEPES, pH 7.6, 1 mM DTT, 100 mM 
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NaCl, 0.2 mM EDTA, 1.5% BSA, 20% glycerol) at 4 °C for 12 h. Samples were separated on NuPAGE gel 
(Invitrogen) and detected.
Co-immunoprecipitation. Cells were harvested at 1000 rpm for 10 min, washed with PBS, and lysed 
with CoIPLysis buffer (1% Triton X-100 containing phosphatase and protease inhibitors). The cell extracts 
were incubated with PBS-washed ANTI-FLAG® M2-Agarose beads at 4°C overnight. After washing with 
lysis buffer and PBS, SDS-loading buffer with β -mercaptoethanol was added and the samples were boiled 
for 5 min. Proteins were separated by SDS-PAGE and detected by ODYSSEY (LI-COR).
In vitro kinase assay. The GST-SMAD fusion proteins were used as substrates. GST-SMD fragments 
were incubated with recombinant PDK4 in kinase buffer and 20 μ M ATP at 37 °C for 30 min. Kinase 
reactions were terminated by addition of NuPAGE loading buffer, heated at 70 °C for 10 min, and sepa-
rated by NuPAGE. Dried gels were exposed to film using an Image Reader FLA-3000 series (FUJUFILM).
Oxygen consumption rate measure. C2C12 cells were plated at 2.0 × 104 cells / well in XF-24 cell 
culture microplate (Seahorse Bioscience, North Billerica, MA, USA). Oxygen consumption rate (OCR) 
was measured the next day using a XF-24 Analyzer (Seahorse Bioscience). Cells were equilibrated for 
1 hour at 37 °C in XF Assay Medium (Seahorse Bioscience) supplemented with 25mM glucose and 1 mM 
sodium pyruvate (pH 7.4) before any measurement. Oligomycin (1 μ M), CCCP (5 μ M) and Rotenone 
(1 μ M) mixture agents were injected to each well consecutively.
Mitochondrial ROS assay53. Human VSMCs were allowed to attach on glass cover slips in 6-well 
plate at a density of 2 × 105 cells per well. Cells were infected with adenovirus expressing PDK4 or CMV 
for 3 h and incubated with growth medium for 48 h. And the other cells were grown to confluence about 
95% after then further incubated in the absence or presence of Pi for the indicated times. Both of cells 
were cultured with MitoTracker Red–CM–H2XROS (M7513, Invitrogen) at a 50 nM final concentration 
followed by incubation for 30 min in a CO2 incubator. Replace the normal media and detected by fluo-
rescence microscope for 5s expose.
Micro-CT analysis. To determine the three-dimensional bone structure in vivo, histomorphometric 
analyses were performed using a Micro-CT system (eXplore Locus SP scanner GE Healthcare) at 8 μ m 
resolution. For details of micro-CT analysis, refer to the supplementary material method.
Statistical analysis. Data are expressed as means ± S.E.M. Statistical analyses were performed using 
an unpaired Student’s t-test. A value of P < 0.05 was considered statistically significant.
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